NICE now recommends Otezla (apremilast) to treat severe psoriasis.- Celgene
The National Institute for Health and Care Excellence (NICE) has changed its position regarding Otezla (apremilast) from Celgene for the treatment of psoriasis subject to Celgene providing a discount via a patient access scheme. Otezla is now recommended for the treatment of severe psoriasis in patients whose disease has not responded to other systemic therapies such as ciclosporin or methotrexate, or these treatments are contraindicated or cannot be tolerated by patients. "Severe" is defined as Psoriasis Area Severity Index (PASI 10) or more and a Dermatology Life Quality Index (DLQI) of more than 10.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.